Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.58 |
| ▸ | HTR1D | P28221 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389745 | 1.00 | HTR1A (1.00) | HTR1AALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL2230435 | 1.00 | HTR1A (1.00) | HTR1AALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL8445391 | 0.90 | ALDH1A1 (0.82) | HTR1AALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL8442534 | 0.89 | HTR1A (0.80) | HTR1AALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL8445633 | 0.89 | HTR1A (0.79) | HTR1AALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL8442467 | 0.88 | HTR1A (0.78) | HTR1AALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL9280040 | 0.87 | HTR1A (0.77) | HTR1AALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL8444594 | 0.87 | HTR1A (0.77) | HTR1AALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL8445766 | 0.87 | HTR1A (0.77) | HTR1AALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL8444593 | 0.87 | HTR1A (0.77) | HTR1AALDH1A1KDM4ECYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-11794009-B2 | Devices, systems and methods for treating urological and gastrointestinal disorders by electrical stimulation of the foot | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-10-24 | — | — | US | claimed |
| US-11426408-B2 | Use of serotonergic drugs to treat virus-induced thrombocytopenia | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-08-30 | — | — | US | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| US-20200352947-A1 | USE OF SEROTONERGIC DRUGS TO TREAT VIRUS-INDUCED THROMBOCYTOPENIA | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2020-11-12 | — | — | US | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| WO-2009090556-A2 | ARTIFICIAL REPRODUCTION OF PHARMACEUTICAL CONDITIONS OF DEPENDENCY TO TOBACCO AND OTHER ADDICTIVE DRUGS (OPIACEA, PSYCHOSTIMULANTS, ALCOHOL) BY COMBINATION OF NICOTINE AND A LIGAND (AGONIST OR 5 ANTAGONIST) OF 5-HT1A RECEPTORS | TASSIN, THOMAS (FR) | 2009-07-23 | — | — | WO | claimed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | claimed |
| WO-2005018541-A2 | COX-2 INHIBITOR AND SEROTONIN MODULATOR FOR TREATING CNS DAMAGE | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | claimed |
| US-12605392-B1 | Cannabinoid composition and method of treating diabetic and chemotherapy induced neuropathic pain | FLORIDA A&M UNIVERSITY (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-12297240-B2 | Peptide | KYOTO UNIVERSITY (JP) | 2025-05-13 | — | — | US | disclosed |
| US-12109221-B2 | Combination therapy for treating cancer | LEUKOS BIOTECH, S.L. (ES) | 2024-10-08 | — | — | US | disclosed |
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | disclosed |
| WO-2005018541-A2 | COX-2 INHIBITOR AND SEROTONIN MODULATOR FOR TREATING CNS DAMAGE | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018569-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | TPH2, TPH1, HTR2A | HTR1A 4/4885ALDH1A1 1103/4885KDM4E 2950/4885 |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | TPH2, TPH1, HTR2A | HTR1A 6/4885ALDH1A1 1946/4885KDM4E 4399/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR1A 4/4885ALDH1A1 913/4885KDM4E 4347/4885 |
| US-12605392-B1 | Cannabinoid composition and method of treating diabetic and chemotherapy induced neuropathic pain | EXOSC10, CNR2, EXOSC9 | HTR1A 1710/4885ALDH1A1 1911/4885KDM4E 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.